JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,830,000 | +4.4% | 61,919 | +2.5% | 0.01% | 0.0% |
| Q3 2017 | $2,711,000 | +52.0% | 60,426 | +1.3% | 0.01% | +50.0% |
| Q2 2017 | $1,783,000 | +15.6% | 59,642 | -14.2% | 0.00% | 0.0% |
| Q1 2017 | $1,542,000 | +24.7% | 69,486 | +5.9% | 0.00% | +33.3% |
| Q4 2016 | $1,237,000 | -31.1% | 65,633 | +9.7% | 0.00% | -40.0% |
| Q3 2016 | $1,795,000 | -15.6% | 59,813 | +8.1% | 0.01% | -16.7% |
| Q2 2016 | $2,128,000 | +421.6% | 55,351 | +417.1% | 0.01% | +500.0% |
| Q1 2016 | $408,000 | -15.4% | 10,704 | -2.3% | 0.00% | -50.0% |
| Q4 2015 | $482,000 | +13.9% | 10,954 | +5.5% | 0.00% | +100.0% |
| Q3 2015 | $423,000 | -18.7% | 10,384 | +6.5% | 0.00% | -50.0% |
| Q2 2015 | $520,000 | – | 9,747 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |